Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Research

• Publication date

  2009-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-08-3886PMID 19351838PMCID PMC2785462
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas.

  2008cited by this paper
• Molecular Cancer BioMed Central

  2008cited by this paper
• Temozolomide preferentially depletes cancer stem cells in glioblastoma.

  2008cited by this paper
• Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61.

  2008cited by this paper
• Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.

  2008cited by this paper
• Malignant gliomas in adults.

  2008cited by this paper
• Molecular strategies for the treatment of malignant glioma—genes, viruses, and vaccines

  2008cited by this paper
• Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses.

  2008cited by this paper
• Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria

  2008cited by this paper
• Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.

  2008cited by this paper
• Oncolytic Herpes Simplex Virus Type-1 Therapy in a Highly Infiltrative Animal Model of Human Glioblastoma

  2008cited by this paper
• Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles.

  2007cited by this paper
• Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death.

  2007cited by this paper
• Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment

  2007cited by this paper
• A perivascular niche for brain tumor stem cells.

  2007cited by this paper
• Neural precursors derived from human embryonic stem cells maintain long‐term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons

  2007cited by this paper
• Cancer stem cells: models and concepts.

  2007cited by this paper
• Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors

  2007cited by this paper
• Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.

  2007cited by this paper
• CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.

  2007cited by this paper
• Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

  2007cited by this paper
• Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression

  2007cited by this paper
• Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells.

  2007cited by this paper
• Enhanced Yield of Neuroepithelial Precursors and Midbrain‐Like Dopaminergic Neurons from Human Embryonic Stem Cells Using the Bone Morphogenic Protein Antagonist Noggin

  2007cited by this paper
• Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases

  2006cited by this paper
• Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

  2006cited by this paper
• Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.

  2006cited by this paper
• Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.

  2006cited by this paper
• Dominant-Negative Fibroblast Growth Factor Receptor Expression Enhances Antitumoral Potency of Oncolytic Herpes Simplex Virus in Neural Tumors

  2006cited by this paper
• Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

  2006cited by this paper
• Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

  2006cited by this paper
• Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.

  2005cited by this paper
• Viral vectors as therapeutic agents for glioblastoma.

  2005cited by this paper
• Recent progress in the battle between oncolytic viruses and tumours

  2005cited by this paper
• Oncolytic viral therapies – the clinical experience

  2005cited by this paper
• Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma

  2004cited by this paper
• Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis

  2004cited by this paper
• Identification of human brain tumour initiating cells

  2004influential reference
• Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis.

  2004cited by this paper
• Isolation of cancer stem cells from adult glioblastoma multiforme

  2004cited by this paper
• Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR

  2004cited by this paper
• Oncolytic herpes simplex virus vectors for cancer virotherapy

  2002cited by this paper
• The Herpes Simplex Virus Type 1 US11 Protein Interacts with Protein Kinase R in Infected Cells and Requires a 30-Amino-Acid Sequence Adjacent to a Kinase Substrate Domain

  2002cited by this paper
• Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing

  2001cited by this paper
• Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

  2000cited by this paper
• Establishment and properties of a growth factor-dependent, perpetual neural stem cell line from the human CNS.

  2000cited by this paper
• Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

  2000cited by this paper
• Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

  1999cited by this paper
• A Herpesvirus Ribosome-Associated, RNA-Binding Protein Confers a Growth Advantage upon Mutants Deficient in a GADD34-Related Function

  1999cited by this paper
• Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

  1995cited by this paper
• Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells.

  1992cited by this paper
• Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture.

  1990cited by this paper

• Recurrent Glioblastoma and the Tumor Immune Landscape: Emerging Immunotherapeutic Strategies

  2026cites this paper
• Human organoid tumor transplantation identifies functional glioblastoma-microenvironment communication mediated by PTPRZ1.

  2026cites this paper
• Combinatorial treatment of glioblastoma with temozolomide (TMZ) plus 5-ethynyl-2′-deoxyuridine (EdU)

  2025cites this paper
• Local therapy with hypoxia-targeting radiopharmaceutical [64Cu]Cu-ATSM in high-grade glioma patient-derived xenograft models.

  2025cites this paper
• HR eye & MMR eye: one-day assessment of DNA repair-defective tumors eligible for targeted therapy

  2025cites this paper
• Dual molecular therapy targeting tumor cell heterogeneity improves therapeutic efficacy in glioblastoma

  2025cites this paper
• Transcription Factor EB Inhibition in Response to Genotoxic Stress Promotes Apoptosis of Glioblastoma Cells.

  2025cites this paper
• Cellular heterogeneity and therapeutic response profiling of human IDH+ glioma stem cell cultures

  2025influential citation
• Repurposing the DNA Labeling Agent EdU for Therapy Against Heterogeneous Patient Glioblastoma.

  2025cites this paper
• CRISPR-Cas9 Gene Editing for Targeting Cancer Stem Cells in Glioblastoma Multiforme

  2025cites this paper
• Oncolytic Virotherapy for Glioma: A Bibliometric Roadmap for Multidisciplinary Clinical and Research Strategies

  2025cites this paper
• Systemic cyst(e)inase administration induces ferroptosis and synergizes with temozolomide in glioblastoma

  2025cites this paper
• Tumor-targeting oncolytic HSV-SUR15 enhances anti-tumor immunity in glioblastoma.

  2025cites this paper
• Choice of Animal Models to Investigate Cell Migration and Invasion in Glioblastoma

  2025influential citation
• Coupling between acid-sensing ion channel 1a and the monocarboxylate transporter family shapes cellular pH response

  2025cites this paper
• Combinatorial Treatment of Glioblastoma with Temozolomide (TMZ) Plus 5-Ethynyl-2’-deoxyuridine (EdU)

  2025cites this paper
• Characterization of pritumumab in murine models and primate safety study

  2025cites this paper
• An oncolytic herpesvirus expressing a CXCR4 antagonist interferes with glioblastoma cells’ stemness features and migration

  2025cites this paper
• Stress-induced pro-inflammatory glioblastoma stem cells secrete TNFAIP6 to enhance tumor growth and induce suppressive macrophages.

  2025cites this paper
• Photodynamic therapy using talaporfin sodium and semiconductor laser induces dose and time dependent cytocidal effect for human glioma derived stem cells.

  2025cites this paper
• Glioblastoma stem cell long non-coding RNAs: therapeutic perspectives and opportunities

  2024cites this paper
• HiTIP-seq profiles epigenomic reprogramming of patient-derived diffuse midline glioma stem cells to epigenetic therapy

  2024cites this paper
• Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo

  2024cites this paper
• Diethyldithiocarbamate-ferrous oxide nanoparticles inhibit human and mouse glioblastoma stemness: aldehyde dehydrogenase 1A1 suppression and ferroptosis induction

  2024cites this paper
• Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells

  2024cites this paper
• Trans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma

  2024cites this paper
• Anatomically aware simulation of patient-specific glioblastoma xenografts

  2024cites this paper
• Establishment and immune phenotyping of patient-derived glioblastoma models in humanized mice

  2024cites this paper
• Red light‐activated depletion of drug‐refractory glioblastoma stem cells and chemosensitization of an acquired‐resistant mesenchymal phenotype

  2024cites this paper
• HOXDeRNA activates a cancerous transcription program and super enhancers via genome-wide binding.

  2024cites this paper
• Local administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumor recurrence in a glioblastoma tumor model

  2024cites this paper
• Immunocompetent murine glioblastoma stem-like cell models exhibiting distinct phenotypes

  2024cites this paper
• Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation

  2024cites this paper
• FUS/circZEB1/miR-128-3p/LBH feedback loop contributes to the malignant phenotype of GSCs via TNF-α-mediated NF-κB signaling pathway

  2024cites this paper
• Brain Organoids: A Game-Changer for Drug Testing

  2024cites this paper
• Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas.

  2024cites this paper
• Pre-Clinical Models for CAR T-Cell Therapy for Glioma

  2024cites this paper
• Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival

  2024influential citation
• HOXDeRNA activates a cancerous transcription program and super-enhancers genome-wide

  2023cites this paper
• Towards deciphering glioblastoma intra‐tumoral heterogeneity: The importance of integrating multidimensional models

  2023cites this paper
• Compensatory cross-talk between autophagy and glycolysis regulates senescence and stemness in heterogeneous glioblastoma tumor subpopulations

  2023cites this paper
• Novel TCF4:TCF12 heterodimer inhibits glioblastoma growth

  2023cites this paper
• Effects of a monoclonal antibody against (pro)renin receptor on gliomagenesis

  2023cites this paper
• Sorting nexin 10 sustains PDGF receptor signaling in glioblastoma stem cells via endosomal protein sorting

  2023cites this paper
• Research Progress in Immunotherapy of Gliomas.

  2023cites this paper
• The tumor-enriched small molecule gambogic amide suppresses glioma by targeting WDR1-dependent cytoskeleton remodeling

  2023cites this paper
• PTEN potentiation of oncolytic HSV therapy for glioblastoma

  2023cites this paper
• Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1

  2023cites this paper
• Multiplex single-cell chemical genomics reveals the kinase dependence of the response to targeted therapy

  2023cites this paper
• Tumor Microenvironment: A Niche for Cancer Stem Cell Immunotherapy

  2023cites this paper
• Recent Progress in Fluorescent Probes for Real-Time Monitoring of Glioblastoma.

  2023cites this paper
• Reticulocalbin 3 Is a Novel Mediator of Glioblastoma Progression

  2023cites this paper
• Fibronectin Type III Domain Containing 3B as a Potential Prognostic and Therapeutic Biomarker for Glioblastoma

  2023cites this paper
• Viral vector‐based cancer treatment and current clinical applications

  2023cites this paper
• Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma

  2023cites this paper
• A living ex vivo platform for functional, personalized brain cancer diagnosis

  2023cites this paper
• Oncolytic virus therapy for malignant gliomas: entering the new era

  2023cites this paper
• Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells

  2023cites this paper
• Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies.

  2023cites this paper
• Glioma Stem Cells in Pediatric High-Grade Gliomas: From Current Knowledge to Future Perspectives

  2022cites this paper
• Differentiated glioma cell-derived fibromodulin activates integrin-dependent Notch signaling in endothelial cells to promote tumor angiogenesis and growth

  2022cites this paper
• The Vascular Microenvironment in Glioblastoma: A Comprehensive Review

  2022cites this paper
• Targeting Glioblastoma Stem Cells to Overcome Chemoresistance: An Overview of Current Therapeutic Strategies

  2022cites this paper
• ISL1 Promotes Human Glioblastoma-Derived Stem Cells' Self-Renewal by Activation of Sonic Hedgehog/GLI1 Function

  2022cites this paper
• Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4+ GBM cells: A proof of principle

  2022cites this paper
• Molecular Mechanisms and Clinical Challenges of Glioma Invasion

  2022cites this paper
• Promoter and enhancer RNAs regulate chromatin reorganization and activation of miR-10b/HOXD locus, and neoplastic transformation in glioma.

  2022cites this paper
• Interferon-γ resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells.

  2022cites this paper
• Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma

  2022cites this paper
• Combination of Ad-SGE-REIC and bevacizumab modulates glioma progression by suppressing tumor invasion and angiogenesis

  2022cites this paper
• Teserpaturev/G47Δ: First Approval

  2022cites this paper
• Advances in immunotherapy for glioblastoma multiforme

  2022cites this paper
• A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma

  2022cites this paper
• miRNome and Proteome Profiling of Small Extracellular Vesicles Secreted by Human Glioblastoma Cell Lines and Primary Cancer Stem Cells

  2022cites this paper
• Current Insights into Mesenchymal Signatures in Glioblastoma.

  2022cites this paper
• Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity

  2022cites this paper
• Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence

  2022cites this paper
• Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy

  2022cites this paper
• The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment

  2021influential citation
• Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells

  2021cites this paper
• Inhibition of glioma using a novel non-neurotoxic vesicular stomatitis virus.

  2021cites this paper
• Oncolytic Viruses and Cancer, Do You Know the Main Mechanism?

  2021cites this paper
• The Strange Case of Jekyll and Hyde: Parallels Between Neural Stem Cells and Glioblastoma-Initiating Cells

  2021cites this paper
• Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF‐kB signaling pathways synergistically

  2021cites this paper
• Neural Stem Cell-Based Therapies and Glioblastoma Management: Current Evidence and Clinical Challenges

  2021cites this paper
• Activation of estrogen receptor beta signaling reduces stemness of glioma stem cells

  2021cites this paper
• In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV

  2021cites this paper
• Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells.

  2021cites this paper
• Combination of Ad-SGE-REIC and Bevacizumab Modulates Glioma Progression by Suppressing Invasion and Angiogenesis

  2021cites this paper
• OV_A_268426 1..27

  2021influential citation
• Diversity in responses to oncolytic Lassa-vesicular stomatitis virus in patient-derived glioblastoma cells

  2021cites this paper
• The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies

  2021influential citation
• Stem Cell Based Modelling of Glioblastoma

  2021cites this paper
• Use of FLOSEAL® as a scaffold and its impact on induced neural stem cell phenotype, persistence, and efficacy

  2021cites this paper
• Integrated Metabolomics and Transcriptomics Analysis of Monolayer and Neurospheres from Established Glioblastoma Cell Lines

  2021cites this paper
• circMELK promotes glioblastoma multiforme cell tumorigenesis through the miR-593/EphB2 axis

  2021cites this paper
• Mouse models of glioblastoma for the evaluation of novel therapeutic strategies

  2021cites this paper
• Developing Implantable Scaffolds to Enhance Neural Stem Cell Therapy for Post-Operative Glioblastoma.

  2020cites this paper
• Multiplexed drug testing of tumor slices using a microfluidic platform

  2020cites this paper
• Drug Repositioning Screen on a New Primary Cell Line Identifies Potent Therapeutics for Glioblastoma

  2020cites this paper